C ytomegalovirus virus (CMV) is a member of the Herpesviridae family. The seroprevalence of CMV varies between 40% and 100% and is influenced by age and geographic distribution, among other factors. 1, 2 In young and healthy adults, CMV is usually characterized by a mild and frequently subclinical course. In immunocompromised patients, CMV may result in a severe systemic disease or end organ damage (such as pneumonitis, hepatitis, and colitis). 3 The role of CMV infection in patients with ulcerative colitis (UC) has been under investigation for over 20 years. Nevertheless, its significance and impact on the course of the disease is still unclear. Although initial reports suggested that patients with UC with CMV colitis have a more severe clinical course and a higher likelihood of colectomy, [4] [5] [6] this association was not supported by various later studies. [7] [8] [9] Although the prevalence of CMV in endoscopic biopsies of patients with severe UC has been described to be as high as 79%, it is unclear whether CMV reactivation is indeed the cause of the exacerbation or a mere evidence of inflammation. 10, 11 Moreover, disappearance of CMV from colonic biopsies after the resolution of the exacerbation without any specific antiviral therapy is well documented. 12 A major limitation of the existing literature stems from the retrospective nature of all included studies, usually featuring a small number of patients and significantly biased by their clinical severity. In a recent meta-analysis that attempted to evaluate the impact of antiviral treatment on the outcome of patients with UC and CMV colitis, patients who were not treated actually fared significantly better. 2 However, this is most likely because of the aforementioned selection bias, with most severe and steroid refractory patients being tested and treated for CMV. In another recent meta-analysis, only corticosteroid-resistant patients benefitted from antiviral therapy. 13 Several studies to date suggested that a higher tissue CMV load may be associated with a worse prognosis. 14, 15 European Crohn's and Colitis organization (ECCO) guidelines recommend an endoscopy with assessment of tissue CMV status in patients hospitalized for UC exacerbation. 16 However, ultimately, a significant gap between the start of treatment and verification of CMV status, and almost all the patients hospitalized for UC exacerbation receive intravenous (IV) corticosteroids (CS) and in many cases a salvage treatment with either infliximab (IFX) or cyclosporine (CsA). The impact of those immunosuppressive treatments on the outcomes of CMV colitis and gancyclovir treatment is unknown.
Therefore, the aim of our study was to evaluate the impact of anti-inflammatory rescue therapy (IFX/CsA) on the outcome of hospitalized CMV-positive patients with severe UC treated with antiviral therapy.
METHODS
This was a multicenter international (Belgium-4 centers, France, Spain, Portugal, Greece-2 centers, Italy, Germany, Slovenia, Denmark, UK, Canada-1 center, Israel-5 centers) retrospective study. We included patients who were hospitalized for UC exacerbation and were positive for CMV on colonic biopsies (by hematoxylin and eosin [HE]/immunohistochemistry [IHC]/quantitative polymerase chain reaction [qPCR]) performed after the admission. To minimize the selection bias by including patients with clinically mild disease, we included only patients who received systemic corticosteroids before or on admission, as well as antiviral (gancyclovir/foscarnet/valgancyclovir) treatment. All patients underwent colonoscopy or sigmoidoscopy after admission. Patients who had a short extent of disease (proctitis) or did not require hospitalization were excluded from the study. Clinical status was established using the partial Mayo score (moderate disease-partial Mayo score .4, severe disease-partial Mayo score .6) 17 or Truelove and Witts criteria as per availability in each participating center. 18 Endoscopic activity was evaluated using the endoscopic Mayo score. 19 CMV status was established by HE or IHC by a gastrointestinal pathologist in each center. Patients diagnosed by quantitative tissue PCR as previously described 14 were also included; CMV load of 10 copies/mg tissue was considered positive. Included patients were classified by their salvage anti-inflammatory treatment.
Group A Received Corticosteroids Only
Group B received corticosteroids and immunosuppressive treatment (IFX-within 30 days before or during hospitalization; CsA-during the course of hospitalization). The main outcome was the risk of colectomy during the index hospitalization or within 30 days of admission. Secondary outcomes included colectomy with 3 and 12 months of the initial admission and risk of recurrence after initial admission.
Statistical Analysis
We used descriptive statistics in percentages with 95% confidence intervals for discrete variables or means with SD for parametric or median with interquartile range (IQR) for nonparametric qualitative variables. For differences in proportions, a chi square test was used; independent samples t test was used for comparison of means. Odds ratios were calculated where appropriate. P value , 0.05 was considered statistically significant. Multivariate regression model was planned if any variable was statistically significant on univariate analysis, For multivariate model, variables with significance level ,0.1 were planned to be included in the model. If no such variables resulted from univariate analysis, the variable with the lowest P value was used along with the statistically significant variable that resulted from the univariate model. The number of variables in the multivariate model was restricted to avoid overfitting. We also performed a Cox regression analysis to investigate the effect of the variables on duration of colectomy-free survival. A Cox proportional hazard analysis model was planned with including variables with significance level , 0.1. The analysis was performed with SPSS version 20.0 (SPSS Inc., Armonk, NY).
The study was approved by the institutional ethic review boards of the participating centers.
RESULTS

Patient Characteristics
A total of 147 hospitalized patients with UC with an evidence of CMV in the colonic mucosa were included form January 2003 to March 2016. After exclusion of patients who were not hospitalized (n ¼ 10), who did not receive corticosteroids (n ¼ 18) before diagnosis, or who did not receive antivirals (n ¼ 9), 110 patients were retained for analysis. Ninety-one (81.7%) of the patients had clinically severe colitis on hospitalization, whereas the rest had moderate disease activity. All patients had at least left-sided colitis (72 [65.5%], extensive colitis), with Mayo score of 3 in 89 (85.5%) of the patients; over 50% started corticosteroid treatment before hospitalization, with a median duration of treatment of 14 (IQR, 7-29) days. Clinical and demographic characteristics of the included patients are summarized in Figure 1 and Table 1 . The patients were followed for 21 (IQR 3-44) months from the index hospitalization.
CMV Infection Characteristics
Tissue CMV results were obtained after a median of 4 (IQR: 3-15) days after the hospitalization. Patients were diagnosed by HE staining alone in 7 (6.4%), HE and IHC in 77 (66.4%) and qPCR in 30 (27.3%) patients. In patients diagnosed by qPCR, the median CMV tissue load was 680 (IQR: 400-3500) copies/mg tissue. CMV IgG status was positive in 88/92 patients with available results (95.7%); CMV IgM was positive in 29/99 (29.3%) of patients with available results. CMV viremia was assessed in 94 patients and was positive in 63 (67%) of the patients. Quantitative blood CMV DNA results were available in 52/ 63 of patients with viremia; in 20/52 (38.5%), blood CMV load was .10,000 copies/mL with a median load of 2400 (IQR: 1200-255,000) copies/mL.
Antiviral Treatment
IV ganciclovir (GCV) was administered for a median of 10 (IQR:7-14) days (5 mg/kg bid). Sixty-eight (61.2%) patients were switched to oral valgancyclovir (median duration of treatment: 14 (IQR: 10-21) days) after IV treatment, and an additional patient was switched to IV foscarnet because of an allergic reaction to gancyclovir. Two patients received only oral valgancyclovir (the IV compound was unavailable at the particular center at the time of index hospitalization).
Anti-inflammatory Treatment
IV corticosteroids were administered in 75 (68.2%) patients before the onset of GCV therapy; the rest of the patients received oral corticosteroids. Forty-seven (42.7%) patients received only antiviral treatment; 36 (32.7%) were exposed to IFX and 23 (20.9%) received IFX during the hospitalization, whereas 13 (11.8%) received IFX within 30 days before hospitalization. Ten of 11 patients who received in-hospital IFX received a single standard dose of 5 mg/kg, 1 patient received 10 mg/kg. One additional patient who received IFX within 30 days before hospitalization received adalimumab and another one vedolizumab. Twenty (18.1%) patients received CsA during hospitalization. Four of these patients received oral cyclosporine (2 continued their oral cyclosporine that was initiated at least 1 year before the hospitalization-for 1 patient after liver transplantation and the other one for refractory UC). Seven patients (6.4%) were exposed to both IFX and CsA during hospitalization (4 failed CsA and switched to IFX and 3 failed IFX and switched to CsA). After confirmation of CMV tissue results, CsA was stopped in 2 patients and continued in 21 patients.
Patient Outcomes
The duration of the index hospitalization was 19.5 (IQR [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] (Fig. 2A) . The results were similar after stratification by types of antiinflammatory therapy (IFX vs CsA vs IFX + CsA) (Fig. 2B , Table 2 ).Although treatment with CsA was associated with a worse outcome at 3 months on univariate analysis (P ¼ 0.046), the result was not significant on multivariate analysis (P ¼ 0.07) (the model included disease extent as an additional variable). None of the other predicting factors, including type of anti-inflammatory medication, CMV viremia, medications on discharge, were associated with the risk of colectomy at any time point ( Table 2) . The results were similar on sensitivity analyses that included patients treated with IV corticosteroids only, diagnosed with IHC/HE only, exposed to IFX during hospitalization only, or after exclusion of patients with moderate clinical or histological disease activity and patients treated with valgancyclovir only (data not shown).
The colectomy-free survival appears in Figure 3 . There were no significant differences between treatment groups (Fig.  4) . On Cox regression analysis, the only variable significantly associated with longer colectomy-free survival was treatment with valgancyclovir after IV gancyclovir treatment (odds ratio: 3.7; 95% confidence interval, 1.7-8.1, P ¼ 0.001). However, the effect was no longer significant if patients who underwent colectomy during the index hospitalization (before the switch to oral treatment) were excluded (odds ratio: 86; 95% confidence interval, 0.23-3.2, P ¼ 0.86). No other variable had a significant effect on the duration of colectomy-free survival (Fig. 4) . One patient with concomitant primary sclerosing cholangitis died during the course of the follow-up after complications of cholangiocarcinoma.
Recurrence
Data on recurrence of CMV colitis was available in 74 patients; clinical recurrence occurred in 10/74 (13.5%) after 9 (6.7-13.2) months. All patients were hospitalized and retreated with IV gancyclovir; 5 of 12 (41.7%) patients underwent colectomy during or after the recurrence episode. No clinical or demographic characteristics were associated with a risk of CMV recurrence (the study was underpowered to discover predictors of CMV recurrence) ( Table 3 ). In 2 patients, CMV presence was accidentally detected on a subsequent endoscopy while in clinical remission. One patient was treated with valgancyclovir and another did not receive any specific treatment; both patients remained in clinical remission for the duration of the follow-up.
DISCUSSION
The current study is the largest to date addressing the outcome of hospitalized patients with severe UC with evidence of CMV presence in the colonic tissue. All patients included in our cohort were hospitalized with an exacerbation of at least moderate severity and required treatment with IV corticosteroids. Our results suggest that patients receiving IFX or CsA in addition to gancyclovir did not have a worse outcome in comparison with those that only received gancylovir. This is a question of a significant importance; as in patients with inflammatory bowel disease (IBD) exacerbation, we assume that immunosuppressive treatment may be a predisposing factor for opportunistic infection. In patients with IBD and concomitant Clostridium difficile infection, combination of antibiotic and anti-inflammatory treatment resulted in a worse outcome. 20 For corticosteroids, the excessive risk of CMV infection associated with even a shortterm treatment is well established. 1 Corticosteroid treatment over a period of at least 3 months at a dose of at least 10 mg was associated with a risk of CMV reactivation, whereas exposure to high-dose corticosteroid treatment is associated with a risk of CMV infection after 7 to 14 days. 21, 22 A high prevalence of CMV was also reported in patients treated with CsA 23, 24 By contrast, anti-tumor necrosis factors and thiopurines do not appear to pose such a risk. 6, 14, [25] [26] [27] In a recent French study, however, it appears that CMV DNA tissue load is negatively associated with a likelihood of response to anti-tumor necrosis factors, 14, 28 and the likelihood of response to anti-tumor necrosis factors is lower in CMV-positive patients. 14, 28 Importantly, all patients in our cohort were treated with corticosteroids in addition to GCV with or without salvage antiinflammatory treatment. We deliberately excluded all patients who were not treated with steroids, as this might have created a significant bias by inclusion of patients with significantly milder disease. In addition, the common clinical set-up or patients with UC exacerbation includes hospitalization with corticosteroid treatment, whereas endoscopic evaluation is usually postponed for hours or days, and processing of histological samples may delay the decision to administer antiviral therapy for much further. However, it appears that treating these with rescue antiinflammatory treatment during this therapeutic window is not harmful. For CsA, the outcome was worse after 3 months (P ¼ 0.046); however, the result was nonsignificant on multivariate analysis.
There is a long-lasting debate regarding the impact of CMV infection on the course of UC exacerbation. 11 Although some studies suggest that the risk of colectomy is higher in CMV-positive patients, others do not confirm such association. [1] [2] [3] 7, 13, 29, 30 All available studies, including the current one are all retrospective studies with huge heterogeneity and significant inclusion bias. A recent meta-analysis in fact demonstrated a higher risk on patients who received gancyclovir; however, this was most likely due to significant bias leading to treatment of the sicker patients while those with a milder disease improved without antiviral treatment. 2 A different meta-analysis demonstrated a significantly increased risk in corticosteroidresistant patients only. 13 Our study was not designed to evaluate the impact of CMV infection on treatment outcomes, as all of our patients were CMV positive and received antiviral treatment or to compare the efficacy of IFX and CsA for treatment of UC exacerbation. Nevertheless, the rate of colectomy was not higher than what was reported for non-CMV-positive population. A third of our patients underwent colectomy within 12 months. There was no significant difference between treatment groups. In fact, even patients who received both GCV and IFX did not have a significantly worse prognosis (although almost 2/3 eventually underwent colectomy, the group was too small to draw achieve clinical significance). [31] [32] [33] [34] Significant variability in the definition of CMV infection is an additional factor that impacts our understanding of its influence on the outcome of UC exacerbation. In fact, in a recent systematic review devoted to definitions of CMV infection in IBD, 21 different definitions were found in the current literature. 3 The prevalence of CMV colitis depends heavily on the definition applied. 11 Although histological techniques such as HE and IHC still constitute the "gold standard" diagnostic modality, 35 the limitations of these techniques include a very low sensitivity of HE 1 and a lack of quantitative standardization for IHC (although 2 recent studies suggested an association between a higher density of CMV-positive cells on IHC and a higher risk of colectomy 9, 15 ). In addition, a high number of biopsy samples are required for an adequate diagnosis. 36 Real-time PCR is significantly more sensitive; however, there are multiple issues with assay standardization and comparability, as well as a high prevalence of positive samples resulting from a remote infection. 1 In our study, we included patients diagnosed with IHC/HE and qPCR-positive patients from a single center with an established expertise with the method (CHU St Etienne). An important positive finding from our study is the significance of continued valgancyclovir therapy after the initial IV gancyclovir phase. In fact, the available guidelines referring to treatment of CMV colitis in IBD are based on data from other disciplines and clinical settings such as posttransplant patients, 35 and no studies evaluating the optimal treatment regimen in patients with IBD are available.
Our study has several limitations. Primarily, this was a multicenter retrospective study that spanned over 12 years. This design has an inherent variability in clinical practices and definitions. We tried to address this limitation by including only hospitalized patients with at least moderate disease activity that required corticosteroid treatment. In addition, we did not perform a revision of pathological samples reviewed by each center. Moreover, our study was underpowered (and not designed as it did not have a control group that did not receive antivirals) to evaluate the impact of antiviral therapy on the outcome of CMVpositive patients or to evaluate the efficacy of individual treatment regimens. It should be mentioned that the risk of colectomy at 1 year in patients treated with IFX/CsA was numerically higher than in those that did not receive those medications; however, the P value did not quite reach statistical significance. We should acknowledge a risk of type II error that may have resulted from an insufficient cohort size or follow-up duration. In addition, the number of patients treated with gancyclovir was small. Most of these patients were hospitalized and treated several years earlier than those that received IFX, so the selection of patients for either treatment was most likely driven by availability and local preference rather than clinical consideration. The number of patients treated by gancyclovir was low and our study was clearly underpowered to compare the risk of colectomy between IFX and gancyclovir.
Despite the aforementioned limitations, our study is the largest to date addressing a relatively homogenous cohort of steroid-resistant severe CMV-positive patients with UC and to study the impact of rescue anti-inflammatory treatment on the outcome of these patients. Our results suggest that treatment with either IFX or cyclosporine does not appear to be harmful, and rescue treatment can be safely initiated without having to wait for CMV assessment results. 
